Literature DB >> 1651557

Prognostic factors in human pancreatic cancer, with special reference to quantitative histology.

M Eskelinen1, P Lipponen, S Marin, H Haapasalo, K Mäkinen, H Ahtola, J Puittinen, P Nuutinen, E Alhava.   

Abstract

A retrospective clinicopathologic study was done on 111 patients with a pancreatic ductal adenocarcinoma. The mean follow-up period was 6 years. By means of interactive morphometry six nuclear morphometric features were measured in biopsy specimens from the primary tumours. Volume-corrected mitotic index (M/V index) was estimated in the same sections. Histologic grading was done in accordance with the WHO. The M/V index (p = 0.002), the nuclear area of the 10 largest nuclei (NA10) (p = 0.025), the histologic grade (p = 0.0956), the nuclear area (NA) (p = 0.038), the standard deviation of the nuclear perimeter (SDPE) (p = 0.033), and the standard deviation of the nuclear area (SDNA) (p = 0.0430) predicted survival in univariate analysis. The type of surgery performed was a significant prognosticator too (p = 0.0131). A multifactor regression analysis of survival including clinical and histologic factors identified the M/V index as the most important prognosticator (p = 0.009), followed by the type of surgery performed (p = 0.022). Other histologic factors had no independent prognostic value. Our results suggest the use of morphometric features instead of the conventional histologic grading in predicting survival of pancreatic ductal adenocarcinoma.

Entities:  

Mesh:

Year:  1991        PMID: 1651557     DOI: 10.3109/00365529108998570

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  9 in total

1.  Mitotic indexes as prognostic predictors in female breast cancer.

Authors:  S Aaltomaa; P Lipponen; M Eskelinen; V M Kosma; S Marin; E Alhava; K Syrjänen
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

2.  Expression of MIB-1, mitotic index and S-phase fraction as indicators of cell proliferation in superficial bladder cancer. Finnbladder Group.

Authors:  T J Liukkonen; P K Lipponen; M Helle; H K Haapasalo; S Nordling; P Rajala
Journal:  Urol Res       Date:  1996

3.  Combined use of nuclear morphometry and DNA ploidy as prognostic indicators in nonresectable adenocarcinoma of the pancreas.

Authors:  S Linder; J Lindholm; U Falkmer; M Blåsjö; P Sundelin; A von Rosen
Journal:  Int J Pancreatol       Date:  1995-12

4.  Predictive value of tumor proliferative indices in periampullary cancers: Ki-67, mitotic activity index (MI) and volume corrected mitotic index (M/V) using tissue microarrays.

Authors:  Mark M Aloysius; Shivanthi J De Silva Hewavisenthi; Timothy E Bates; Brian J Rowlands; Dileep N Lobo; Abed M Zaitoun
Journal:  World J Surg       Date:  2010-09       Impact factor: 3.352

5.  Prognostic value of histological grading in ductal adenocarcinoma of the pancreas. Klöppel vs TNM grading.

Authors:  P C Giulianotti; U Boggi; G Fornaciari; J Bruno; G Rossi; D Giardino; G Di Candio; F Mosca
Journal:  Int J Pancreatol       Date:  1995-06

6.  Prognostic factors in WHO grade 2 transitional-cell bladder cancer (TCC); a novel two-grade classification system for TCC based on mitotic index.

Authors:  P K Lipponen; M J Eskelinen; K Jauhiainen; E Harju; P Terho; H Haapasalo
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

7.  Vinblastine and 5-fluorouracil sensitivity of xenografts of four pancreatic ductal adenocarcinomas: is there a correlation with histological and cytological tumour differentiation?

Authors:  A Vergeylen; G Klöppel
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

8.  Clinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinoma.

Authors:  P A Pasanen; M Eskelinen; K Partanen; P Pikkarainen; I Penttilä; E Alhava
Journal:  Br J Cancer       Date:  1992-05       Impact factor: 7.640

9.  The growth pattern and microvasculature of pancreatic tumours induced with cultured carcinoma cells.

Authors:  K Mäkinen; S Loimas; P Nuutinen; M Eskelinen; E Alhava
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.